Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). Available data documents that cannabis is effective in the treatment of chronic pain and may potentially mitigate symptoms of post-traumatic stress, along with other conditions commonly facing veterans.
Representatives Lou Correa (D-CA) and Clay Higgins (R-LA) and Senators Jon Tester (D-MT) and Dan Sullivan (R-AK) have introduced legislation, HR 712 / S. 179: The VA Medicinal Cannabis Research Act of 2019 to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.
Post-traumatic stress, chronic pain, and other medical issues can be a matter of life or death. Moreover, failure of VA policy to allow physicians to openly talk about cannabis or recommend it has a deleterious effect on the doctor-patient relationship and on the well-being of our veterans.
Lawmakers have removed language from pending federal legislation that sought to facilitate veterans’ access to medical cannabis in jurisdictions that regulate it.
Senators Brian Schatz (D-HI) and Bill Nelson (D-FL) today introduced legislation, The Veterans Medical Marijuana Safe Harbor Act, to expand and facilitate medical cannabis access to military veterans suffering from chronic pain, PTSD, and other serious medical conditions.
Today, Congressman Charlie Crist held a press conference to announce the introduction of the Fairness in Federal Drug Testing Under State Laws Act, HR 6589.
The House Rules Committee led by prohibitionist Representative Pete Sessions (R-TX) blocked multiple amendments related to marijuana from receiving consideration by the full House, thus ending their consideration and silencing the ability for the lower chamber to offer protections for veterans who use cannabis for therapeutic purposes from Attorney General Jeff Sessions.
Patients enrolled in New York state’s medical cannabis program reduce their use of opioids and spend less money on prescription medications, according to data published online in the journal Mental Health Clinician. “After three months treatment, medical cannabis improved [subjects’] quality of life, reduced pain and opioid use, and lead to cost savings,” authors concluded.
United States Rep. Timothy Waltz (D-MN), along with over 30 bipartisan co-sponsors, has introduced legislation, HR 5520: The VA Medicinal Cannabis Research Act of 2018, to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.
Members of the US House Committee on Veteran’s Affairs are demanding the Department of Veterans Affairs facilitate protocols to assess the efficacy of medical cannabis in veterans suffering from chronic pain and post-traumatic stress.